Vanguard Group Inc. Boosts Stock Holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Vanguard Group Inc. increased its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 6.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,020,570 shares of the company’s stock after purchasing an additional 126,139 shares during the quarter. Vanguard Group Inc. owned approximately 0.20% of Teva Pharmaceutical Industries worth $18,649,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Point View Wealth Management Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 1.7% during the second quarter. Point View Wealth Management Inc. now owns 74,798 shares of the company’s stock valued at $690,000 after purchasing an additional 1,273 shares during the period. Northstar Group Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 8.4% during the second quarter. Northstar Group Inc. now owns 20,568 shares of the company’s stock valued at $190,000 after purchasing an additional 1,600 shares during the period. AGF Investments America Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the 2nd quarter. AGF Investments America Inc. now owns 91,897 shares of the company’s stock worth $848,000 after acquiring an additional 1,672 shares during the last quarter. WealthTrust Axiom LLC raised its holdings in shares of Teva Pharmaceutical Industries by 15.0% in the 2nd quarter. WealthTrust Axiom LLC now owns 13,049 shares of the company’s stock worth $120,000 after acquiring an additional 1,700 shares during the last quarter. Finally, Hartford Investment Management Co. raised its holdings in shares of Teva Pharmaceutical Industries by 6.6% in the 2nd quarter. Hartford Investment Management Co. now owns 28,324 shares of the company’s stock worth $261,000 after acquiring an additional 1,748 shares during the last quarter. 58.21% of the stock is currently owned by institutional investors.

A number of equities research analysts have issued reports on the stock. Morgan Stanley downgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $16.00 to $6.00 in a research report on Monday, July 15th. Wolfe Research began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 price objective for the company. Guggenheim began coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating for the company. UBS Group set a $8.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, August 16th. Finally, Raymond James cut their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Six investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $10.78.

Teva Pharmaceutical Industries stock traded up $0.83 during trading hours on Friday, reaching $9.30. The stock had a trading volume of 34,192,717 shares, compared to its average volume of 16,922,125. The company has a fifty day simple moving average of $7.51 and a 200-day simple moving average of $8.90. The stock has a market cap of $9.32 billion, a PE ratio of 3.32, a PEG ratio of 0.89 and a beta of 1.73. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. Teva Pharmaceutical Industries Ltd has a 52 week low of $6.07 and a 52 week high of $23.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 EPS. Research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Book Value Of Equity Per Share – BVPS Explained

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.